Avista Healthcare
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif. (November 1, 2022) – OmniAb, Inc. (NASDAQ: OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and the subsequent business combination with Avista Public Acquisition Corp. II […]
Avista to leverage industry expertise to support Taconic’s growth in the large and expanding GEMs market NEW YORK, November 1, 2022 — Avista Capital Partners (“Avista”), a leading private equity firm focused exclusively on healthcare, today announced its acquisition of Taconic Biosciences (“Taconic” or the “Company”), a leading provider of genetically engineered research models (GEMs) and related […]
Extraordinary General Meeting of APAC Shareholders to Vote on Proposed Business Combination with OmniAb to be Held on October 24, 2022 NEW YORK (October 3, 2022) – Avista Public Acquisition Corp. II (NASDAQ: AHPA) (“APAC”) announced today the effectiveness of the Registration Statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) in […]
About the Acquisition Vision Healthcare reached an agreement with the shareholders of AixSwiss BV for the acquisition of 100% of the shares in AixSwiss BV (“AixSwiss” or the “Company”), a leading DACH e-commerce player active in probiotic nutraceutical supplements commercialised under the “Nupure” brand mainly through its own e-store, Amazon and e-pharma channels. AixSwiss was […]
Combination establishes a one-stop shop for efficient end-to-end solutions that facilitate chemical compound procurement and management for highly specialized chemists SAN DIEGO and NEWARK, Del., Sept. 7, 2022 /PRNewswire/ — eMolecules, Inc., provider of a leading chemistry search-and-fulfillment platform for early drug discovery research, today announced the acquisitions of Frontier Scientific Inc. (FSI) and Frontier Agricultural Sciences […]
Avista to leverage its expertise and resources to accelerate WellSpring’s growth trajectory for the benefit of all stakeholders NEW YORK, August 23, 2022 — Avista Capital Partners (“Avista”), a leading private equity firm focused exclusively on healthcare, today announced the completion of its acquisition of WellSpring Consumer Healthcare (“WellSpring”), a developer and marketer of leading over-the-counter (“OTC”) […]
TAMPA, Fla.– Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair, and service, announced the acquisition of Mi Healthcare. Terms of the transaction were not disclosed. Established in 1995, Mi Healthcare is a Liverpool, United Kingdom-based provider of medical imaging equipment and services to public and private healthcare facilities across the […]
BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that it has entered into arrangements to secure up to $68.9 million in committed financing through a combination of equity and non-dilutive […]
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry BLUE BELL, Pa., July 28, 2022 /PRNewswire/ — UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, today announced that it has acquired Examoto, LLC, a Risk Evaluation and Mitigation Strategy (REMS) company. Examoto is dedicated […]
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Conference call and webcast to be held today at 8:30 a.m. […]
NEW YORK, April 27, 2022 — Avista Capital Partners (“Avista”), a leading private equity firm focused exclusively on healthcare, today announced that it has closed on the sale of Inform Diagnostics (“Inform Diagnostics”) to Fulgent Genetics (NASDAQ: FLGT). Inform Diagnostics is one of the largest national pathology laboratories in the United States with offerings across gastrointestinal […]
Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent’s rapidly expanding genomic testing footprint Preliminary first quarter revenue results expected to exceed previous guidance provided on February 23, 2022 Fulgent updates full year 2022 core revenue guidance to approximately $175 million […]